These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 2672339

  • 1. Lineage-specific requirement of c-abl function in normal hematopoiesis.
    Caracciolo D, Valtieri M, Venturelli D, Peschle C, Gewirtz AM, Calabretta B.
    Science; 1989 Sep 08; 245(4922):1107-10. PubMed ID: 2672339
    [Abstract] [Full Text] [Related]

  • 2. Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors.
    Rosti V, Bergamaschi G, Lucotti C, Danova M, Carlo-Stella C, Locatelli F, Tonon L, Mazzini G, Cazzola M.
    Blood; 1995 Nov 01; 86(9):3387-93. PubMed ID: 7579442
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides.
    Szczylik C, Skórski T, Malaguarnera L, Hetman J, Chen ST, Calabretta B.
    Folia Histochem Cytobiol; 1996 Nov 01; 34(3-4):129-34. PubMed ID: 8967957
    [Abstract] [Full Text] [Related]

  • 4. A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations.
    Chasty R, Whetton A, Lucas G.
    Leuk Res; 1996 May 01; 20(5):391-5. PubMed ID: 8683978
    [Abstract] [Full Text] [Related]

  • 5. c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers.
    Rosti V, Bergamaschi G, Ponchio L, Cazzola M.
    Leukemia; 1992 Jan 01; 6(1):1-7. PubMed ID: 1736009
    [Abstract] [Full Text] [Related]

  • 6. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ.
    Leuk Lymphoma; 1995 Dec 01; 20(1-2):67-76. PubMed ID: 8750625
    [Abstract] [Full Text] [Related]

  • 7. A functional analysis of protooncogene Vav's role in adult human hematopoiesis.
    Luger SM, Ratajczak J, Ratajczak MZ, Kuczynski WI, DiPaola RS, Ngo W, Clevenger CV, Gewirtz AM.
    Blood; 1996 Feb 15; 87(4):1326-34. PubMed ID: 8608221
    [Abstract] [Full Text] [Related]

  • 8. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.
    Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM.
    Proc Natl Acad Sci U S A; 1991 Mar 15; 88(6):2351-5. PubMed ID: 2006173
    [Abstract] [Full Text] [Related]

  • 9. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
    Skorski T, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szcyzlik C, Chen ST, Lange B, Calabretta B.
    J Clin Invest; 1993 Jul 15; 92(1):194-202. PubMed ID: 8325984
    [Abstract] [Full Text] [Related]

  • 10. Role of the KIT protooncogene in normal and malignant human hematopoiesis.
    Ratajczak MZ, Luger SM, DeRiel K, Abrahm J, Calabretta B, Gewirtz AM.
    Proc Natl Acad Sci U S A; 1992 Mar 01; 89(5):1710-4. PubMed ID: 1371882
    [Abstract] [Full Text] [Related]

  • 11. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
    Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R.
    J Clin Invest; 1993 Oct 01; 92(4):1925-39. PubMed ID: 8408645
    [Abstract] [Full Text] [Related]

  • 12. Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis.
    Caracciolo D, Venturelli D, Valtieri M, Peschle C, Gewirtz AM, Calabretta B.
    J Clin Invest; 1990 Jan 01; 85(1):55-61. PubMed ID: 2404028
    [Abstract] [Full Text] [Related]

  • 13. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
    Lin H, Monaco G, Sun T, Ling X, Stephens C, Xie S, Belmont J, Arlinghaus R.
    Oncogene; 2005 May 05; 24(20):3246-56. PubMed ID: 15735695
    [Abstract] [Full Text] [Related]

  • 14. p120 GAP requirement in normal and malignant human hematopoiesis.
    Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak M, Szczylik C, Zon G, Arlinghaus RB, Gewirtz A, Perussia B, Calabretta B.
    J Exp Med; 1993 Dec 01; 178(6):1923-33. PubMed ID: 8245773
    [Abstract] [Full Text] [Related]

  • 15. Raf-1 protein is required for growth factor-induced proliferation of hematopoietic cells.
    Muszynski KW, Ruscetti FW, Heidecker G, Rapp U, Troppmair J, Gooya JM, Keller JR.
    J Exp Med; 1995 Jun 01; 181(6):2189-99. PubMed ID: 7539043
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation.
    Murohashi I, Endho K, Nishida S, Yoshida S, Jinnai I, Bessho M, Hirashima K.
    Exp Hematol; 1995 Aug 01; 23(9):970-7. PubMed ID: 7543418
    [Abstract] [Full Text] [Related]

  • 17. Enforced TAL-1 expression stimulates primitive, erythroid and megakaryocytic progenitors but blocks the granulopoietic differentiation program.
    Valtieri M, Tocci A, Gabbianelli M, Luchetti L, Masella B, Vitelli L, Botta R, Testa U, Condorelli GL, Peschle C.
    Cancer Res; 1998 Feb 01; 58(3):562-9. PubMed ID: 9458106
    [Abstract] [Full Text] [Related]

  • 18. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B.
    J Natl Cancer Inst; 1997 Jan 15; 89(2):124-33. PubMed ID: 8998181
    [Abstract] [Full Text] [Related]

  • 19. Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides.
    Gewirtz AM.
    Bone Marrow Transplant; 1994 Jan 15; 14 Suppl 3():S57-61. PubMed ID: 7697011
    [No Abstract] [Full Text] [Related]

  • 20. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro.
    Gewirtz AM, Calabretta B.
    Science; 1988 Dec 02; 242(4883):1303-6. PubMed ID: 2461588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.